AstraZeneca Extends Tempus AI Partnership with $200 Million Commitment as Analyst Weighs Multiplesbenzinga_article·Nov 19, 2026 at 05:18 PMAZN-1.87%TEM-6.30%
3 ETFs That Hold AstraZeneca In Very Different WaysSimplywall·Nov 19, 2026 at 03:29 PMAZN-1.87%EWU-1.37%
Lupus Research Alliance and Clinical Affiliate Lupus Therapeutics Form New Collaboration with AstraZeneca to Advance Drug Development in Lupusprnewswire·Nov 19, 2026 at 01:34 PMAZN-1.87%AZN
Roche Completes USD300 Million Shanghai Plant, Eyes Local Production of Eye Drug by 2028Yicai·Nov 19, 2026 at 11:37 AMRHHBY-0.87%RHHVF+0.46%
AstraZeneca's sonesitatug vedotin gets FDA priority review for advanced gastric cancersPUBT·Nov 19, 2026 at 07:14 AMAZN-1.87%AZN
Tempus AI secures $200 million five-year commitment from AstraZenecaPUBT·Nov 18, 2026 at 01:34 PMAZN-1.87%TEM-6.30%
How Investors Are Reacting To Nestlé (SWX:NESN) Regen Farming PactSimplywall·Nov 17, 2026 at 05:23 PMNSRGF-0.14%
AZ beefs up myasthenia gravis pedigree with US, EU Klygefa nodsFiercepharma·Nov 16, 2026 at 03:43 PMAZN-1.87%AZN
AstraZeneca Secures Dual Rare Disease and Bladder Cancer Approvals Across US, Europebenzinga_article·Nov 16, 2026 at 12:52 PMAZN-1.87%AZNCF
China Adds Record 51 Innovative Drugs to Public Medical Insurance CatalogYicai·Nov 16, 2026 at 11:44 AMAZN-1.87%NVO-1.42%
Sofinnova Partners backs European life sciences sector with €725M raisePharmaceutical Technology·Nov 16, 2026 at 09:53 AMABVX-3.79%AHKSY-1.82%
AstraZeneca secures FDA approval for Imfinzi combo in MIBCPharmaceutical Technology·Nov 16, 2026 at 09:37 AMAZN-1.87%AZN
AstraZeneca: Alexion's Klygefa Gets EU Approval To Treat Adults With Generalised Myasthenia Gravisrttnews·Nov 16, 2026 at 07:45 AMAZN-1.87%AZN
REG - AstraZeneca PLC - Baxfendy recommended for approval in the EULondon Stock Exchange·Nov 16, 2026 at 07:15 AMAZN-1.87%AZN